The role of insulin resistance in HIV/hepatitis C virus-coinfected patients

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 553-558

  Eslam, Mohammed ^a   López Cortés, Luis F ^b   Romero Gomez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

HIV HCV coinfection; insulin resistance; liver fibrosis; sustained virological response

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; DISEASE COURSE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FIBROSIS; META ANALYSIS (TOPIC); MIXED INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 80054897004     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bd21d     Document Type: Review

References (44)

1. Rockstroh JK, Spengler U. HIv and hepatitis Cvirus co-infection. Lancet Infect Dis 2004; 4:437-444.
2. Sulkowski MS, Thomas DL. Hepatitis C in the HIv-infected patient. Clin Liver Dis 2003; 7:179-194. (Pubitemid 36350759)
3. vDube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005 19: 1807-1818. (Pubitemid 41546599)
4. Grunfeld C, Kotler DP, Arnett DK, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008; 118:e20-e28.
5. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIv coinfection shortens the survival of patients with hepatitisC virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789. (Pubitemid 40462940)
6. Giordano TP, Kramer JR, Souchek J, et al. Cirrhosis and hepatocellular carcinoma in HIv-infected veterans with and without the hepatis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-2354. (Pubitemid 39532246)
7. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis of the impact of insulin resistance on sustained virological response in Hepatitis C. Aliment Pharmacol Ther 2011; 34:297-305.
8. Halfon P, Pénaranda G, Carrat F, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCv) mono-infected compared with HIv-HCv co-infected patients. Aliment Pharmacol Ther 2009; 30:61-70.
9. Berson SA, Yalow RS. In: Ellenberg M, Rifkin H, editors. Diabetes mellitus: theory and practice, New York: McGraw-Hill, 1970; pp. 388-423.
10. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15:318-368.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
12. Miller WG, Thienpont LM, van Uytfanghe K, et al. Insulin Standardization Work Group et al. Toward standardization of insulin immunoassays. Clin Chem 2009; 55:1011-1018.
13. Staten MA, Stern MP, Miller WG, et al. Insulin Standardization Work Group et al. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010; 33:205-206.
14. Heinemann L. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care: response to Staten et al. Diabetes Care 2010; 33:e83.
15. Slama L, Le Camus C, Serfaty L, et al. Metabolic disorders and chronic viral disease: the case of HIv and HCv. Diabetes Metab 2009; 35:1-11.
16. Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52:38-46.
17. Cacoub P, Carrat F, Bédossa P, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIv-hepatitis C virus-coinfected patients: HOMAvIC-ANRS HC02 Study. Antivir Ther 2009; 14:839-845.
18. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS Cohort Study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
19. The data collection on adverse events of anti-HIv drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
20. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIv protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254. (Pubitemid 30457596)
21. Kim RJ, Wilson CG, Wabitsch M, et al. HIv protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006; 14:994-1002. (Pubitemid 46219700)
22. Ben-Romano R, Rudich A, Tirosh A, et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 2004; 47:1107-1117. (Pubitemid 38918171)
23. del Campo JA, López RA, Romero-Gómez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. Dig Dis 2010; 28:285-293.
24. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosisa nd antiretroviral drug use among adults coinfected with HIv and hepatitis C virus. AIDS 2005; 19:585-592. (Pubitemid 40543981)
25. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIv-HCv coinfected patients: analysis of risk factors. AIDS 2006; 20:525-531. (Pubitemid 43731596)
26. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIv and hepatitis C virus. J Infect Dis 2005; 192:1943-1949. (Pubitemid 41681892)
27. Merchante N, Macías J, Ramayo E, et al. Insulin resistance is not associated with Liver fibrosis progression in HIv/hepatitis C virus-coinfected patients. J viral Hep 2006; 13:449-456.
28. Merchante N, Rivero A, de Los Santos-Gil I, et al. Insulin resistance is associated with Liver stiffness in HIv/HCv co-infected patients. Gut 2009; 58:1654-1660.
29. Sánchez-Conde M, Montes Ramírez ML, Bellón Cano JM, et al. Impact of Liver steatosis on the correlation between Liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virus. J viral Hepat 2011; 18:e278-e283.
30. Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virologic response in HIv/hepatitis C virus coinfected patients on peginterferonalfa- 2a. AIDS 2008; 22:857-861. (Pubitemid 351563835)
31. Ryan P, Resino S, Miralles P, et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIv and hepatitis C virus. J Acquir Immune Defic Syndr 2010; 55:176-181.
32. Merchante N, de los Santos-Gil I, Merino D, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIv/HCv co-infected patients. J Hepatol 2009; 50:684-692.
33. vachon ML, Factor SH, Branch AD, et al. Insulin resistance predicts retreatment failure in an efficacy study of peginterferon-a-2a and ribavirin in HIv/HCv co-infected patients. J Hepatol 2011; 54:41-47.
34. Donato C, Cingolani A, Pinnetti C, De Luca A. Insulin resistance and HCv virologic response to peg-interferons (Peg-IFN) with ribavirin (RBv) in HIv/ HCv co-infected patients. J Hepatol 2010; 52:306-307.
35. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIv-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010; 10:183.
36. Romero-Gómez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50:1702-1708.
37. Georgescu EF, Streba L, Teodorescu R, et al. Potential Enhancement of both early and sustained virological response by fluvastatin in chronic hepatitis C treated with standard peginterferon'ribavirin theraphy. A pilot study. J Hepatol 2011; 54:S5.
38. Ikeda M, Abe K, Yamada M, et al. Different anti-HCv profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44:117-125. (Pubitemid 44049145)
39. Delang L, Paeshuyse J, vliegen I, et al. Statins potentiate the in vitro antihepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50:6-16.
40. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864-874.
41. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140:144-152.
42. Milazzo L, Meroni L,Galazzi M, et al. Does fluvastatin favour HCv replication in vivo? A pilot study on HIv-HCv coinfected patients. J viral Hepat 2009; 16:479e84.
43. Milazzo L, Caramma I, Mazzali C, et al. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIv/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010; 65:735-740.
44. Hickman IJ, Clouston AD, MacDonald GA, et al. Effect of weight reduction on Liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51:89-94 (Pubitemid 34717750)